As sartans continued to struggle, the problem expanded in 2019
In March, we reported that a new generic valsartan (Diovan) hit the market to help the angiotensin receptor blocker (ARB) shortage caused by waves of recalls. In this follow-up, we take a look at the developments in the nitrosamine impurity problem that are now affecting other classes of drugs.